The animal models services global market is
expected to grow at single digit CAGR to reach $962.2 million by 2025. For
hundreds of years, almost every medical breakthrough in human and animal health
has been the result of research using animals. Animals in research are
essential for the development of new and more effective methods for diagnosis
and treatment of diseases that affect both humans and animals. Animals are used
to learn more about health problems, and to assure the safety of new medical
treatments.
Classical pharmacological models or animal
models are used as a mandatory element in preclinical (toxicological and
pharmacological) studies of new drugs. Although in recent years, the
replacement of animal testing and animal models with in-vitro models has been
increasingly introduced into practice, according to the modern manuals of
pharmaco-toxicological preclinical study, some animal studies still remain
compulsory.
For approval of the first phase clinical trials
it is mandatory to submit preclinical pharmacological, toxicological and
pharmacokinetic findings. Toxicology testing provides information about the
conditions under which potentially useful for humans drugs may become toxic.
These tests are used to assess the possible adverse reactions and the nature of
the target organ. Other tests for determining the dosage range which define:
the maximum dose at which no adverse effects are noticed; the lowest observed
adverse effect level; the maximum feasible/tolerated dose (MFD/MTD), the
therapeutic index as a ratio between LD50/ED50 also use animals at the
preclinical stage.
These animal studies are compared and
extrapolated to determine relevant data for humans based on the animal species
similarity to humans. Prior to testing in humans, results from animal models
allow solely the formation of the untested hypothesis of human response. For
example, if a compound shows lowering blood pressure activity in rats, the
chances of such activity in humans are high. However, these approaches use of
relatively large quantities of the new compound (usually around 5 g), and the
required time and money. Furthermore, they also provide little or no
information about the molecular mechanisms behind the observed effects.
Animal model studies have also been seen as
an approach towards accidental discovery of drug effects discovered in clinical
practice. For example, the diuretic effect of sulphanilamide and acetazolamide
as carbonic anhydrase inhibitors; making them suitable for discovery of new
biologics, as biologics are complex large compounds that are sometimes not well
understood at molecular level. Animal models are biologically similar to humans
and share a common physiology. They have a shorter life cycle making it convenient
for study. Also, it is easy to control the animal environment, unlike that of
humans. The success of animal model depends on animal model selection, which
again depends on the species, breeds and strains, which have close resemblance
with the humans.
Spanning over 159 pages “Animal
Model Services Global Market - Forecast to 2025” report covers Animal
Model Services Global Market, Executive Summary, Market Analysis, Animal Model
Services, Company Profiles. This Report Covered 75 Companies Few Are - Advinus
Therapeutics, Beijing Vital Star Biotechnology Co. Ltd., Charles River Laboratories,
Crown Biosciences, Envigo, Genoway, Horizon Discovery Group, Plc, Jackson
Laboratory, Pharmalegacy, Pharmaron, Psycogenics Inc, Shanghai Medicilon,
Sobran Biosciences, Syngene International, Taconic Biosciences.
Please visit this link for more details: http://mrr.cm/ULv
Find all Pet
Care Services Reports
at: http://www.marketresearchreports.com/pet-care-services
No comments:
Post a Comment
Note: only a member of this blog may post a comment.